Developer docs
API playgroundTry for free, no card

Search company profiles

OneThree Biotech

Full company profile

uuid000211m

Namestring
OneThree Biotech
Websiteurl
onethree.bio
Company typeenum
Private
Founded yearint
2018
Short descriptiontext

OneThree Biotech is a New York-based, privately held AI-driven drug discovery company founded in 2018. It applies biology-driven artificial intelligence to redesign early-stage drug discovery workflows for pharmaceutical and biotechnology partners, operating with a small technical team of 11–50 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
AI drug discovery, computational biology, drug target identification, precision medicine, biotech AI platform
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery Platform
Social media profiles2 records
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

OneThree Biotech redesigns drug discovery by applying biology-driven artificial intelligence to identify and validate novel therapeutic targets and drug candidates. The company builds computational biology and machine learning models that leverage biological data to accelerate early-stage drug discovery for pharmaceutical and biotechnology partners.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1OneThree Biotech AI Drug Discovery Platform
CategoryAI Drug Discovery Software
Description

A biology-driven artificial intelligence platform that identifies and validates novel therapeutic targets and drug candidates for pharmaceutical and biotechnology partners engaged in early-stage drug discovery.

No data
Peers10 records
TypeDirect peer
Description

Exscientia builds AI-designed drug candidates and has signed multi-asset collaborations with major pharma, comparable to what an AI-discovery startup like OneThree aspires to grow into.

TypeDirect peer
Description

XtalPi combines AI, physics-based modeling, and lab automation for drug discovery, sharing the AI-discovery-for-pharma business model that OneThree is pursuing.

TypeDirect peer
Description

Cyclica uses AI and proteome-wide screening to support drug discovery and polypharmacology, comparable to OneThree as a smaller AI-native platform targeting pharma partnerships.

TypeDirect peer
Description

Atomwise uses AI for small-molecule drug discovery, including target identification and hit optimization. It is directly comparable as an AI-native platform pitching pharma collaborations in the same buyer pool as OneThree.

TypeBroad incumbent
Description

Schrödinger offers a broad computational chemistry and biology platform widely used in drug discovery programs, providing overlapping AI/ML-driven molecular design capabilities and serving the same pharma R&D customer base.

TypeDirect peer
Description

Recursion combines high-throughput biology with AI/ML to discover and develop drugs at scale, overlapping strongly with OneThree's biology-driven AI approach for target identification.

7Isomorphic Labs
TypeBroad incumbent
Description

Alphabet's Isomorphic Labs applies AI to drug discovery, sharing the AI-augmented pharma-partnership business model though operating at vastly greater scale and capital intensity than OneThree.

TypeDirect peer
Description

Insitro applies machine learning to biological data to predict which drugs will be effective, closely matching OneThree's biology-driven AI drug discovery thesis. Both target partnerships with large pharma using ML-augmented target identification and validation.

9BPGbio
TypeEmerging player
Description

BPGbio (formerly Berg Pharma) uses AI-driven biology for drug discovery and target identification, overlapping with OneThree's biology-driven AI for pharma R&D use cases.

TypeDirect peer
Description

BenevolentAI applies AI to biomedical knowledge graphs for drug discovery and target identification, operating in the same biology-first AI-for-drug-discovery category as OneThree.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OneThree Biotech

AI Drug Discovery Platformonethree.bio

OneThree Biotech is a New York-based, privately held AI-driven drug discovery company founded in 2018. It applies biology-driven artificial intelligence to redesign early-stage drug discovery workflows for pharmaceutical and biotechnology partners, operating with a small technical team of 11–50 employees.

OneThree Biotech firmographics

Firmographics
Name
OneThree Biotech
Website
https://onethree.bio
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
OneThree Biotech is a New York-based, privately held AI-driven drug discovery company founded in 2018. It applies biology-driven artificial intelligence to redesign early-stage drug discovery workflows for pharmaceutical and biotechnology partners, operating with a small technical team of 11–50 employees.
Ownership category
akta.pro rank

OneThree Biotech industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Computational biology
  • Drug target identification
  • Precision medicine
  • Biotech AI platform

Where OneThree Biotech is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

OneThree Biotech business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

OneThree Biotech product offering

Product offering

Core offering

OneThree Biotech redesigns drug discovery by applying biology-driven artificial intelligence to identify and validate novel therapeutic targets and drug candidates. The company builds computational biology and machine learning models that leverage biological data to accelerate early-stage drug discovery for pharmaceutical and biotechnology partners.

Differentiator

Problem solved

Functional benefit

Products and services

  • OneThree Biotech AI Drug Discovery Platform A biology-driven artificial intelligence platform that identifies and validates novel therapeutic targets and drug candidates for pharmaceutical and biotechnology partners engaged in early-stage drug discovery.

Companies that use OneThree Biotech

Customer profile

Ideal customer profiles1 record

OneThree Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

OneThree Biotech competitors and assessment

Company assessment

Direct peers

  • Exscientia: Exscientia builds AI-designed drug candidates and has signed multi-asset collaborations with major pharma, comparable to what an AI-discovery startup like OneThree aspires to grow into.
  • XtalPi: XtalPi combines AI, physics-based modeling, and lab automation for drug discovery, sharing the AI-discovery-for-pharma business model that OneThree is pursuing.
  • Cyclica: Cyclica uses AI and proteome-wide screening to support drug discovery and polypharmacology, comparable to OneThree as a smaller AI-native platform targeting pharma partnerships.
  • Atomwise: Atomwise uses AI for small-molecule drug discovery, including target identification and hit optimization. It is directly comparable as an AI-native platform pitching pharma collaborations in the same buyer pool as OneThree.
  • Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML to discover and develop drugs at scale, overlapping strongly with OneThree's biology-driven AI approach for target identification.
  • Insitro: Insitro applies machine learning to biological data to predict which drugs will be effective, closely matching OneThree's biology-driven AI drug discovery thesis. Both target partnerships with large pharma using ML-augmented target identification and validation.
  • BenevolentAI: BenevolentAI applies AI to biomedical knowledge graphs for drug discovery and target identification, operating in the same biology-first AI-for-drug-discovery category as OneThree.

Broad incumbents

  • Schrödinger: Schrödinger offers a broad computational chemistry and biology platform widely used in drug discovery programs, providing overlapping AI/ML-driven molecular design capabilities and serving the same pharma R&D customer base.
  • Isomorphic Labs: Alphabet's Isomorphic Labs applies AI to drug discovery, sharing the AI-augmented pharma-partnership business model though operating at vastly greater scale and capital intensity than OneThree.

Emerging players

  • BPGbio: BPGbio (formerly Berg Pharma) uses AI-driven biology for drug discovery and target identification, overlapping with OneThree's biology-driven AI for pharma R&D use cases.

Market position

Customer concentration

OneThree Biotech social profiles

Digital presence

OneThree Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OneThree Biotech leadership team

Management profile

Number of profiles

Profiles4 records

OneThree Biotech funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OneThree Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OneThree Biotech

What does OneThree Biotech do?

OneThree Biotech redesigns drug discovery by applying biology-driven artificial intelligence to identify and validate novel therapeutic targets and drug candidates. The company builds computational biology and machine learning models that leverage biological data to accelerate early-stage drug discovery for pharmaceutical and biotechnology partners.

When was OneThree Biotech founded?

OneThree Biotech was founded in 2018. It employs 1 to 10 people.

Where is OneThree Biotech based?

OneThree Biotech is headquartered in New York, United States, in the North America region.

Who are OneThree Biotech's main competitors?

Direct peers on record are Exscientia, XtalPi, Cyclica, Atomwise, Recursion Pharmaceuticals, Insitro and BenevolentAI. Broad incumbents are Schrödinger and Isomorphic Labs. BPGbio is listed as an emerging player.

Does OneThree Biotech have an API?

No public API is recorded for OneThree Biotech.

What industry is OneThree Biotech in?

OneThree Biotech's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CrowleylawllcAI-Driven Drug Discovery: Innovations and Legal InsightsCrowley Law LLC provides legal services focused on intellectual property and regulatory compliance for companies utilizing artificial intelligence in biotechnology and drug discovery. The article highlights how AI accelerates research and development, citing examples like OneThree Biotech and Talking Medicines, while emphasizing the need for robust legal frameworks to protect innovations and ensure data privacy. It outlines the firm's expertise in navigating patent laws, product liability risks, and regulations such as HIPAA and GDPR.techbuzzirelandPoolbeg Pharma signs AI deal with OneThree Biotech to identify new drug targets and treatments for RSVPoolbeg Pharma signed an agreement with OneThree Biotech to use AI to identify new drug targets and treatments for RSV. The analysis will prioritize drugs with existing Phase I safety data, with work starting in Q1 2022 and preliminary outputs expected in H2 2022. OneThree will receive milestone payments and royalties.PR NewswireOneThree Biotech Joins Forces with SPARC to Characterize a Key Oncologic PathwayOneThree Biotech announced a collaboration with Sun Pharma Advanced Research Company Ltd. (SPARC) to use AI to characterize an enzyme pathway involved in oncogenesis, aiming to advance precision oncology drug discovery. OneThree Biotech will apply its proprietary database integrating over 40 types of data from 100+ sources combined with its AI platform to identify key drivers in the oncologic pathway and optimal cancer subtypes. The partnership is expected to generate insights to identify patient populations sensitive to specific treatments and potential single and combination therapies for preclinical and clinical development.PR NewswireJubilant Therapeutics and OneThree Biotech Collaborate to Advance Precision OncologyJubilant Therapeutics and OneThree Biotech announced the successful completion of a collaborative study using AI-powered biomarker discovery to advance Jubilant's dual epigenetic inhibitor (JBI-802) targeting melanoma, MDS, AML, and solid tumors. The study generated data supporting the LSD1/HDAC6 dual inhibition mechanism, identified molecular markers for patient selection, and determined additional target indications for future trials. IND-enabling studies are underway with first-in-human clinical trials expected to begin in 2021.AlleyWatchOneThree Biotech Raises $2.5M to Disrupt Drug DiscoveryOneThree Biotech raised $2.5M to apply AI to drug discovery, focusing on uncovering mechanisms of action for cancer therapies. The company claims to have reduced trial time from four years to months in one proof of concept. It is also offering free compound toxicity screening for COVID-19 research.PR NewswireOneThree Biotech Announces $2.5M Seed Funding & Free Toxicity Screening for Small Molecules Treating COVID-19OneThree Biotech closed a $2.5M seed round co-led by Primary Venture Partners and Meridian Street Capital. The company will use the funds to scale its biology-driven AI platform and offer free toxicity screening to researchers developing COVID-19 treatments. The platform has validated its approach through a Phase 2 trial with Oncoceutics.Cornell ChronicleAl Algorithm Predicts Drug Targets, Leads to Promising Results for Experimental Cancer TreatmentWeill Cornell Medicine scientists published a paper in Nature Communications on Nov. 19 describing BANDIT, a machine-learning algorithm trained on data from over 2,000 drug compounds to predict which enzymes or receptors a prospective drug targets. The tool helped a pharmaceutical company repurpose ONC201 as a glioma treatment, showing long-term regressions in some previously resistant patients. The researchers are co-founders of OneThreeBiotech.GlobeNewswireOneThree Biotech Wins “Best in Show” at 1st Pitch Life Science CompetitionOneThree Biotech won Best in Show at MABA's 1st Pitch Life Science event on March 13, 2017, in New York City. The company's AI platform identifies drug targets and side effects with up to 90 percent accuracy. CEO Neel Madhukar said the feedback will shape future business development.